Erschienen in:
01.01.2016 | Case report
Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer
verfasst von:
Noriko Goda, Yoshiharu Kawabuchi, Masanobu Watari, Takashi Kumada, Tomohiro Kondo, Satoshi Inoue, Takuro Yamaguchi, Yuta Kuroo, Atsushi Nakamitsu
Erschienen in:
International Cancer Conference Journal
|
Ausgabe 1/2016
Einloggen, um Zugang zu erhalten
Abstract
Pyopneumothorax is a rare but troubling complication of bevacizumab. We herein report a case of pyopneumothorax in a patient with metastatic breast cancer during bevacizumab treatment. A 60-year-old female who was diagnosed with metastatic breast cancer (ER+ , PgR+ , HER2-, Ki67 <14 %, metastasized to lung, pleural, brain, subcutaneous tissue, and bone) was started on bevacizumab plus paclitaxel chemotherapy. Although the disease was well-controlled, pyopneumothorax was noted after 3 months of treatment and the chemotherapy was therefore stopped immediately. The pyopneumothorax was so intractable that no conservative treatment could successfully manage it. The patient underwent a radical operation using the technique of latissimus dorsi muscle transfer. The operation improved her general condition and lead to hormonal therapy. Our case indicates the successful management of a severe side effect of bevacizumab for a breast cancer patient.